Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6121 to 6135 of 8314 results

  1. Cost effectiveness:- What is the cost effectiveness of interventions to prevent infection and promote the appropriate use of antimicrobials?

    Recommendation ID NG63/1 Question Cost effectiveness:- What is the cost effectiveness of interventions to prevent infection and promote

  2. Follow-up:- What is the optimal method, frequency and duration of follow-up for people who are disease-free after treatment for CUADT?

    Recommendation ID NG36/5 Question Follow-up:- What is the optimal method, frequency and duration of follow-up for people who are disease-free

  3. HPV testing:- What is the comparative effectiveness of single-step laboratory diagnostic tests to identify human papillomavirus (HPV) against current diagnostic test algorithms and reference standards in people with cancer of the oropharynx?

    Recommendation ID NG36/2 Question HPV testing:- What is the comparative effectiveness of single-step laboratory diagnostic tests to identify

  4. Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification when selecting which people with CUADT would benefit from short- or long-term enteral nutrition?

    Recommendation ID NG36/4 Question Enteral nutrition support:- What specific clinical and non-clinical factors allow risk stratification

  5. Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary, can radiotherapy target volumes be selected based on clinical and pathological factors?

    Recommendation ID NG36/3 Question Unknown primary of presumed upper aerodigestive tract origin:- In people with CUADT of unknown primary

  6. Systemic imaging – who and why?:- What factors determine the risk of a person presenting with CUADT having metastasis or a second primary cancer?

    Recommendation ID NG36/1 Question Systemic imaging – who and why?:- What factors determine the risk of a person presenting with CUADT having

  7. Further information about MTAC registration and meetings

    More detail about Medical Technologies Advisory Committee (MTAC) registration, meeting arrangements and types of attendee.

  8. Further information about IPAC registration and meetings

    More detail about Interventional Procedures Advisory Committee (IPAC) registration, meeting arrangements and types of attendee.

  9. Further information about DAC registration and meetings

    More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.

  10. Board members

    Our board sets out our strategic priorities and policies. It has 2 sub-committees, the audit and risk assurance committee and the remuneration committee.

  11. NICE's prioritisation process explained – what healthtech developers need to know

    Understand why we're prioritising key topic areas for evaluation and what it means for innovators

  12. Changes to NICE's cost-effectiveness thresholds confirmed

    The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.

  13. Seven digital platforms supporting at home cardiac rehab given conditional recommendations

    People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.

  14. Chief executive's end of year message

    Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.

  15. Newly recommended CBT therapies could help children and young people deal with anxiety

    NICE conditionally recommends digital cognitive behaviour therapies (CBT) for use in the NHS to help children and young people with symptoms of mild to moderate anxiety